Respiratorius AB (publ) is a pharmaceutical company based in Lund, specializing in the development of innovative drugs for cancer treatment, with a particular focus on Diffuse large B-cell lymphoma. The company is engaged in creating a diverse project portfolio that targets various drug candidates, aiming for either drug launch or out-licensing opportunities. This strategic approach is designed to enhance their research and development efforts and facilitate market entry.
The company collaborates with strategic partners to bolster its research initiatives, reflecting a commitment to advancing therapies that can improve patient outcomes in oncology. Respiratorius AB is guided by an experienced Board of Directors and leadership team, which supports its clear business concept centered on drug innovation. The organization prioritizes cutting-edge research in the field of oncology, positioning itself to contribute significantly to advancements in cancer treatment.